stoxline Quote Chart Rank Option Currency Glossary
  
Bionano Genomics, Inc. (BNGO)
0.9635  -0.02 (-1.98%)    05-30 15:52
Open: 0.98
High: 1.02
Volume: 1,067,299
  
Pre. Close: 0.983
Low: 0.95
Market Cap: 64(M)
Technical analysis
2024-05-30 3:13:09 PM
Short term     
Mid term     
Targets 6-month :  1.41 1-year :  1.65
Resists First :  1.21 Second :  1.41
Pivot price 1.05
Supports First :  0.91 Second :  0.74
MAs MA(5) :  1.01 MA(20) :  1.02
MA(100) :  1.1 MA(250) :  2.56
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  31.7 D(3) :  41.3
RSI RSI(14): 46.7
52-week High :  8.19 Low :  0.7
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ BNGO ] has closed above bottom band by 17.4%. Bollinger Bands are 34% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.03 - 1.04 1.04 - 1.04
Low: 0.96 - 0.96 0.96 - 0.97
Close: 0.97 - 0.98 0.98 - 0.99
Company Description

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

Headline News

Wed, 29 May 2024
Bionano (BNGO) to Report Q2 Earnings: What's in the Cards? - Yahoo Movies Canada

Tue, 28 May 2024
Bears are Losing Control Over Bionano Genomics, Inc. (BNGO), Here's Why It's a 'Buy' Now - Yahoo Movies UK

Tue, 14 May 2024
Bionano Genomics, Inc. (BNGO) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Movies Canada

Fri, 10 May 2024
Bionano Genomics Inc Stock Quote | Stock Price for BNGO | FinancialContent Business Page - Financial Content

Wed, 08 May 2024
Bionano Genomics, Inc. (BNGO) Q1 2024 Earnings Call Transcript - Seeking Alpha

Fri, 05 Apr 2024
BioNano Genomics Launches Offering to Bolster Finances - TipRanks.com - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Shares Out 67 (M)
Shares Float 55 (M)
Held by Insiders 0.3 (%)
Held by Institutions 10 (%)
Shares Short 5,360 (K)
Shares Short P.Month 5,470 (K)
Stock Financials
EPS -6.81
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.09
Profit Margin 0 %
Operating Margin -270 %
Return on Assets (ttm) -33.4 %
Return on Equity (ttm) -134.6 %
Qtrly Rev. Growth 30.5 %
Gross Profit (p.s.) 0
Sales Per Share 0.54
EBITDA (p.s.) -1.89
Qtrly Earnings Growth 0 %
Operating Cash Flow -125 (M)
Levered Free Cash Flow -98 (M)
Stock Valuations
PE Ratio -0.15
PEG Ratio 0
Price to Book value 0.46
Price to Sales 1.8
Price to Cash Flow -0.53
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android